

Reference Number: FOI202223/572
From: Commercial
Date: 06 February 2023
Subject: Use of Biologic medicines in gastroenterology

Q1 How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- a. Adalimumab - Humira
- b. Adalimumab Biosimilar
- c. Filgotinib
- d. Golimumab
- e. Infliximab - Remicade
- f. Infliximab Biosimilar
- g. Ozanimod
- h. Tofacitinib
- i. Upadacitinib
- j. Ustekinumab
- k. Vedolizumab

A1 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.

Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Crohn's Disease ONLY with the following biologic drugs:

- a. Adalimumab - Humira
- b. Adalimumab Biosimilar
- c. Golimumab
- d. Infliximab - Remicade
- e. Infliximab Biosimilar
- f. Upadacitinib
- g. Ustekinumab
- h. Vedolizumab

A2 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.